ELITE PHARMACEUTIC COM USD0.01 (ELTP)

0.19
OTC Markets
Prev Close 0.19
Day Low/High 0.19 / 0.21
52 Wk Low/High 0.15 / 0.44
Exchange OTC Markets
Shares Outstanding 730.97B
Market Cap 141.81M
Div & Yield N.A. (N.A)

Elite Announces U.S. FDA Priority Review Designation For SequestOx™ NDA

SequestOx™ NDA Submission Accepted for Review

Elite Pharmaceuticals, Inc. Reports Strong Growth For Third Quarter Of Fiscal Year 2016

Conference Call Scheduled for Wednesday, February 10th at 11:30 AM EST

Elite Pharmaceuticals, Inc. To Host Conference Call To Discuss 3rd Quarter 2016 Financial Results On February 10, 2016

Financials for 3rd Quarter Ended December 31, 2015 Will be Released on February 9, 2016

FDA Approves Waiver Of NDA Filing Fee For Elite Pharmaceuticals

Elite to Submit New Drug Application for ELI-200

Elite Pharmaceuticals, Inc. Reports Strong Growth For Second Quarter Of Fiscal Year 2016

Webcast and Conference Call Scheduled for Tuesday, November 10th at 11:00 AM EST

Elite Pharmaceuticals, Inc. To Host Conference Call And Webcast To Discuss 2nd Quarter 2016 Financial Results On November 10, 2015

Financials for 2nd Quarter Ended September 30, 2015 will be released on November 9, 2015

Elite Pharmaceuticals, Inc. Reports Record Revenues For First Quarter Of Fiscal Year 2016

Webcast and Conference Call Scheduled for Tuesday, August 11th at 11:00 AM EDT

Elite Pharmaceuticals Announces Launch Of Generic Hydroxyzine Tablets

Elite Pharmaceuticals Completes Dosing for Two ELI-200 Studies

Elite Pharmaceuticals, Inc. To Host Quarterly Business Update Call On Wednesday, February 18, 2015

Third Quarter Financials for Fiscal Year 2015 Are Scheduled to Be Filed on Tuesday, February 17, 2015